New drug combo for liver cancer passes safety check in 1,200 patients
NCT ID NCT05667064
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at the safety of two drugs, IMJUDO and IMFINZI, given together or alone to 1,200 people with advanced liver cancer that cannot be removed by surgery. The main goal was to track any side effects that happen in everyday medical use. The study is now complete and helps doctors understand the real-world risks of this treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UNRESECTABLE HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can an IDO1 inhibitor boost immunotherapy against liver cancer?
- AI takes on liver cancer: could a computer help pick the right immunotherapy?
- Immunotherapy combo tested against untreatable liver cancer
- Liver cancer drug combo shows promise in large trial
- New hope for liver cancer patients with cirrhosis? tiny trial tests drug duo
- New radioactive beads aim to outperform standard liver cancer therapy